Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small airway dysfunction: a key predictor of exacerbation risk in adolescents with mild, well-controlled asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Delayed Diagnosis of Cystic Fibrosis and Nontuberculous Mycobacterial Infection in Refractory CRSwNP.

Respirology case reports·2026
Same author

Interpreting Win Ratios in COPD From BOREAS and NOTUS.

Chest·2026
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma.

Clinical and translational allergy·2026
Same author

BAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review.

BMJ open respiratory research·2026

Related Experiment Video

Updated: Jan 13, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.1K

Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD.

Philipp Suter1, Robert Greig1, Rory Chan1

  • 1Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom.

The Journal of Allergy and Clinical Immunology. in Practice
|January 9, 2026
PubMed
Summary

Airway hyper-responsiveness (AHR) in chronic obstructive pulmonary disease (COPD) is linked to type 2 inflammation and may benefit from targeted therapies. Further research is needed to clarify its role in personalized COPD management.

Keywords:
Airway hyper-responsivenessAsthma COPD overlapCOPDType 2 inflammation

More Related Videos

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
13:10

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique

Published on: May 15, 2013

58.2K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.3K

Related Experiment Videos

Last Updated: Jan 13, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.1K
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
13:10

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique

Published on: May 15, 2013

58.2K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.3K

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Clinical Immunology
  • Pharmacology

Background:

  • Airway hyper-responsiveness (AHR), common in asthma, is under-recognized in chronic obstructive pulmonary disease (COPD).
  • Increasing recognition of COPD heterogeneity, including eosinophilic COPD and asthma-COPD overlap, highlights AHR as a marker for type 2 (T2) inflammation.
  • This T2-high phenotype affects 20-40% of COPD patients, driving interest in biologics targeting IL-4, IL-5, IL-13, and TSLP.

Purpose of the Study:

  • To review current evidence on AHR in COPD.
  • To explore the relationship between AHR, inflammatory phenotypes, diagnostic methods, and therapeutic implications in COPD.
  • To assess AHR as a potential treatable trait in COPD management.

Main Methods:

  • Review of existing literature on AHR in COPD.
  • Analysis of diagnostic modalities: direct challenges (e.g., methacholine) assessing airway geometry vs. indirect challenges (e.g., mannitol) reflecting T2 inflammation.
  • Correlation of AHR with inflammatory markers like eosinophils and fractional exhaled nitric oxide (FeNO).

Main Results:

  • AHR in COPD involves both structural and inflammatory mechanisms.
  • Indirect challenges correlate better with T2 inflammation markers (eosinophils, FeNO) than direct challenges.
  • Patients with AHR may respond better to inhaled corticosteroids; biologics show promise but require specific COPD trials.

Conclusions:

  • AHR is a clinically relevant trait in COPD, especially in T2-high phenotypes.
  • Standardized AHR challenges, inflammatory marker integration, and targeted biologic trials are crucial for personalized COPD management.
  • AHR represents a promising treatable trait for optimizing COPD therapy.